9 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
High-risk gestational trophoblastic neoplasia is the aggressive form of this pregnancy-related cancer, usually choriocarcinoma that has spread to the lungs, liver or brain and produces very high hCG. It is treated with the multi-drug EMA-CO regimen, started gently in the sickest women to avoid early deaths, and most are cured; resistant disease gets platinum regimens, immunotherapy or surgery.
High-risk gestational trophoblastic neoplasia, a FIGO 2000 score of 7 or more, is usually gestational choriocarcinoma, a tumour of syncytiotrophoblast and cytotrophoblast that follows a molar, term, miscarried or ectopic pregnancy and spreads through the blood to the lungs, vagina, liver and brain; it bleeds readily and produces enormous amounts of hCG. Choriocarcinoma after a term pregnancy is often diagnosed late because nobody suspects it, and any woman of reproductive age with unexplained metastases should have an hCG measured. Multi-agent chemotherapy became standard in the 1980s when Kenneth Bagshawe's group at Charing Cross developed EMA-CO (etoposide, methotrexate and actinomycin D alternating weekly with cyclophosphamide and vincristine), with which five-year survival was 86 percent in the Charing Cross cohort of 272 women (1997) and overall survival 94 percent in its 1995 to 2010 cohort, and which the FIGO 2021 report calls the most commonly used regimen.
The main causes of death are early haemorrhage and organ failure in women with very high tumour burden, and late resistance. For ultra-high-risk disease (score 13 or more, or liver or brain metastases) the Charing Cross centre reported (2013) that starting with one to three weekly cycles of low-dose etoposide and cisplatin before EMA-CO was followed by an early death rate of 0.7 percent, against 7.2 percent in its earlier cohort, and brain metastases are treated with higher-dose intrathecal or systemic methotrexate with or without radiotherapy or surgery. Women whose hCG plateaus on EMA-CO switch to EP-EMA (etoposide and cisplatin alternating with EMA) or to TP/TE (paclitaxel with cisplatin alternating with paclitaxel and etoposide), which cure most of the remainder; hysterectomy, lung resection or excision of a resistant focus localised by PET can remove the last chemoresistant deposit, and high-dose chemotherapy with autologous stem cell rescue has cured a few. Because trophoblast expresses PD-L1, pembrolizumab was reported effective in drug-resistant disease in the first case series (Lancet 2017), and camrelizumab with apatinib gave complete responses in 10 of 20 women after at least two failed multi-drug regimens in the single-arm CAP 01 trial (Lancet Oncology 2021). The PD-L1 antibody avelumab did not repeat its low-risk result here: it normalised hCG in 1 of 7 women resistant to multi-agent chemotherapy, and that TROPHIMMUN cohort was stopped for futility (Gynecologic Oncology 2023). hCG follow-up runs for at least a year, often longer, before pregnancy is allowed, and late effects of etoposide, including a small excess of leukaemia, are monitored.
| Setting | Approach | Guideline |
|---|---|---|
| Staging | hCG, chest CT, brain MRI, abdominal imaging, pelvic Doppler ultrasound and FIGO scoring; genotyping where the antecedent pregnancy is unclear. | not mapped |
| High-risk disease, first line | EMA-CO (etoposide, methotrexate, actinomycin D alternating with cyclophosphamide and vincristine) until hCG normalises plus at least three consolidation cycles. | not mapped |
| Ultra-high-risk disease | Induction low-dose etoposide and cisplatin for one to three cycles before EMA-CO to prevent early death from haemorrhage and organ failure. | not mapped |
| Brain metastases | High-dose systemic and intrathecal methotrexate within EMA-CO, with whole-brain or stereotactic radiotherapy or craniotomy for bleeding or single lesions. | not mapped |
| Resistant or relapsed disease | EP-EMA or TP/TE; resection of a resistant focus (hysterectomy, lung wedge); pembrolizumab (avelumab normalised hCG in only 1 of 7 women after multi-agent chemotherapy in TROPHIMMUN cohort B); high-dose chemotherapy with autologous rescue in exceptional cases. | not mapped |